aamc.org does not support this web browser. Learn more about the browsers we support.

New section

Content Background

New section

Senate HELP Committee Approves Califf Nomination to Lead FDA

January 14, 2022

New section

New section

CONTACTS
Christa Wagner, Manager, Government Relations

The Senate Health, Education, Labor, and Pensions (HELP) Committee approved the nomination of Robert Califf, MD, to lead the Food and Drug Administration (FDA) in a Jan. 13 executive session.

Bipartisan members of the HELP Committee, including Chair Patty Murray (D-Wash.) and Ranking Member Richard Burr (R-N.C.), supported Califf’s nomination in a final vote of 13-8. Califf previously appeared before the committee on Dec. 14 for his nomination hearing [refer to Washington Highlights, Dec. 17, 2021].

In advance of Califf’s nomination hearing, AAMC President and CEO David J. Skorton, MD, submitted a Dec. 13, 2021, letter to the committee in support of the nomination. “Dr. Califf’s previous experience as FDA commissioner and as deputy commissioner of the Office of Medical Products and Tobacco will allow a seamless transition to the role and help ensure stability in the midst of the persisting public health emergency,” Skorton wrote. The AAMC previously issued a press statement following the announcement of Califf’s nomination on Nov. 12, 2021 [refer to Washington Highlights, Nov. 12, 2021].

New section

New section